AKTX (Akari Therapeutics) Cash Flow for Dividends: $0.00 Mil (TTM As of Mar. 2026)

What is Akari Therapeutics Cash Flow for Dividends?

Akari Therapeutics AKTX -7.39% 32 Cash Flow for Dividends is $0.00 Mil as of Mar. 2026. GuruFocus rates AKTX with a GF Score™ of 32/100.

Akari Therapeutics's cash flow for dividends for the three months ended in Mar. 2026 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Akari Therapeutics Cash Flow for Dividends Related Terms

Akari Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Akari Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics Cash Flow for Dividends Chart

Akari Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash Flow for Dividends

Get a 7-Day Free Trial

0.00

Akari Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash Flow for Dividends	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

32GF Score

Akari Therapeutics PLC AKTX

Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Akari Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequently Asked Questions Learn more about Cash Flow for Dividends →

What does a Cash Flow for Dividends of $0.00 Mil mean?

Akari Therapeutics (AKTX) has a Cash Flow for Dividends of $0.00 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Akari Therapeutics and its competitors.

Is Akari Therapeutics' Cash Flow for Dividends too high?

Akari Therapeutics' current Cash Flow for Dividends is $0.00 Mil. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Akari Therapeutics' Cash Flow for Dividends compare to MBRX and JAGX?

Akari Therapeutics' Cash Flow for Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash Flow for Dividends for a Biotechnology company?

A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash Flow for Dividends mean?

A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Akari Therapeutics and its competitors. Akari Therapeutics's current Cash Flow for Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Akari Therapeutics stock overvalued right now?

Akari Therapeutics (AKTX) has a current Cash Flow for Dividends of $0.00 Mil. The current Cash Flow for Dividends is $0.00 Mil. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash Flow for Dividends calculated?

Cash Flow for Dividends is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current Cash Flow for Dividends is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies MBRX JAGX ANEB XCUR BCDA GRTX CELU TVRD HOWL KTTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602

Website https://www.akaritx.com

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

32GF Score

Get the complete analysis for AKTX

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.94

Price

View AKTX Analysis

See Cash Flow for Dividends data for all stocks →